All figures shown in the chart above are for the trailing 12 month (TTM) period

Revenue missed analyst estimates by 10%. Earnings per share (EPS) exceeded analyst estimates.

Looking ahead, revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.

We don't want to rain on the parade too much, but we did also find 3 warning signs for Elutia (1 is a bit concerning!) that you need to be mindful of.